GSDME-mediated pyroptosis in microglia exacerbates demyelination and neuroinflammation in multiple sclerosis: insights from humans and cuprizone-induced demyelination model mice.

Researchers investigated a biological process called pyroptosis in brain cells that may worsen multiple sclerosis (MS), a disease where the protective coating around nerves breaks down. Scientists studied brain tissue from MS patients and mice with similar nerve damage, focusing on a protein called GSDME that triggers cell death and inflammation. They found that GSDME levels were significantly elevated in the brains of MS patients, particularly in immune cells called microglia at injury sites. When researchers removed the GSDME gene in mice, the animals showed better movement, less nerve coating damage, and reduced brain inflammation. The study revealed that GSDME affects how microglia function, preventing them from properly cleaning up damaged myelin debris through a recycling process called autophagy. When GSDME was blocked, microglia were better able to clear this debris and promote nerve repair. This inflammatory cell death process appears to create a harmful cycle: damaged nerve coatings trigger microglial activation, which leads to more inflammation and further nerve damage. While this research doesn't directly involve acupuncture, understanding MS mechanisms is crucial for integrative care approaches. Acupuncture has been explored for managing MS symptoms like pain, fatigue, and muscle spasms, and some patients report improved quality of life. This new research suggests that reducing neuroinflammation could be key to slowing MS progression, which aligns with acupuncture's anti-inflammatory effects observed in other conditions. If you have MS and are considering acupuncture as part of your care plan, work with a licensed acupuncturist experienced in neurological conditions and coordinate with your neurologist.

This study identifies GSDME-mediated pyroptosis in microglia as a critical mechanism driving demyelination and neuroinflammation in multiple sclerosis. Researchers analyzed brain tissues from MS patients and utilized cuprizone (CPZ)-induced demyelination mice models. Key findings include significantly elevated GSDME expression in CNS lesions of MS patients with pronounced cleavage in microglial cells. Genetic knockout of Gsdme in mice resulted in improved motor function, reduced demyelination, and decreased neuroinflammation. Caspase-3 inhibition similarly suppressed GSDME activation with therapeutic benefits. Transcriptome sequencing revealed GSDME regulates disease-associated microglia (DAM) gene expression and impairs microglial autophagy, compromising myelin debris clearance. Gsdme knockout upregulated remyelination-related genes (Cybb, Cd74) while downregulating DAM-associated genes. In vitro studies confirmed GSDME suppression enhanced microglial autophagy and debris clearance. Clinical implications: This research establishes GSDME as a potential therapeutic target for MS. While sample sizes weren't specified, findings suggest anti-inflammatory interventions targeting the caspase-3/GSDME pathway may reduce neuroinflammation and support remyelination, relevant considerations for integrative MS management protocols.